Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.
Anne-Gaëlle GoubetLeonardo LordelloCarolina Alves Costa SilvaIsabelle PeguilletMarianne GazzanoMaxime Descartes Mbogning FonkouCassandra ThelemaqueCedric LebacleConstance ThibaultFrancois AudenetGéraldine PignotGwenaëlle GravisCarole HelisseyLuca CampedelMorgan RoupretEvanguelos XylinasIdir OuzaidAgathe DubuissonMarine MazzengaCaroline FlamentPierre LyVirginie MartyNicolas SignolleAllan SauvatThomas SbarratoMounia FilahiCaroline DavinGabriel HaddadJacques Yb KhalilCamille BlériotFrançois-Xavier DanlosGarett DunsmoreKevin MulderAymeric SilvinThibault RaoultBaptiste ArchambaudShaima BelhechmiIvo Gomperts BonecaNadège CayetMaryse Moya-NilgesAdeline MalletRomain DaillèreEtienne RouleauCamelia RadulescuYves AlloryJacques FieschiMathieu RouanneFlorent GinhouxGwénaël Le TeuffLisa DerosaAurélien MarabelleJeroen van DorpNick van DijkMichiel S Van Der HeijdenBenjamin BesseFabrice AndreMiriam MeradGuido KroemerJean Yves ScoazecLaurence ZitvogelYohann LoriotPublished in: Cancer discovery (2022)
In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli-specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies. This article is highlighted in the In This Issue feature, p. 2221.
Keyphrases